Navigation Links
The Multiple Myeloma Research Consortium (MMRC) and Proteolix Initiate Phase 2 Clinical Trial Investigating Carfilzomib for the Treatment of Multiple Myeloma
Date:8/19/2007

l benefit response (CBR), time to progression (TTP), duration of response (DOR), progression-free survival, and best ORR throughout the study. Patients enrolled in the trial will receive carfilzomib twice weekly for three weeks every 28 days.

"Based on promising laboratory and clinical data, we believe that carfilzomib holds promise in treating patients with multiple myeloma, including those for whom other treatments have failed," said Sundar Jagannath, M.D., Saint Vincent's Comprehensive Cancer Center, where the first patient was enrolled. "We are excited to bring this compound into the MMRC as a critical step in bringing this new treatment to patients."

In the coming weeks, the MMRC and Proteolix will also begin enrolling an open-label, single-arm, Phase 2 study of carfilzomib in patients with relapsed multiple myeloma, who will be stratified by bortezomib (Velcade(R), Millennium Pharmaceuticals, Inc.) history.

About Carfilzomib

Carfilzomib is a structurally- and mechanistically-novel proteasome inhibitor that exhibits a high level of selectivity for the unique N-terminal threonine active sites within the proteasome. Carfilzomib is similar to bortezomib in that it is a potent inhibitor of the proteasome chymotrypsin- like activity, but unlike bortezomib, carfilzomib has shown minimal cross- reactivity with the other catalytic sites within the proteasome or across other protease classes. Phase 1 clinical studies confirmed that patients who have relapsed or progressed following multiple therapies can still achieve durable anti-tumor responses with carfilzomib. In addition to the two Phase 2 single-agent trials in myeloma and ongoing studies in lymphoma, a clinical trial in solid tumors and a trial exploring carfilzomib in combination with an FDA-approved agent will be initiated by the end of the year.

"The Phase 1 data consistently demonstrate carfilzomib anti-tumor activity in myeloma patients who have failed multiple lines of therapy,
'/>"/>

SOURCE Proteolix

Copyright©2007 PR Newswire.

Page: 1 2 3 4

Related medicine technology :

1. Keryx Biopharmaceuticals, Inc. Announces Positive Phase I and Phase II Data on KRX-0401 in Patients with Relapsed/Refractory Multiple Myeloma and Waldenstroms Macroglobulinemia
2. Velcade (Bortezomib) for Injection Based Therapies Produced Complete Remission Rates as High as 54 Percent in Patients With Previously Treated Multiple Myeloma
3. Velcade (bortezomib) for Injection Based Therapies Achieved Survival Rates as High as 100 Percent in Newly Diagnosed Multiple Myeloma Patients
4. Gentiums Defibrotide Seen as Active in Multiple Myeloma
5. ACE-011 Improves Multiple Myeloma Bone Disease in a Preclinical Model
6. New Data from Multiple Studies Show Galvus Delivers Consistent and Robust Blood Sugar Control in Patients with Type 2 Diabetes
7. CytRx Announces Clinical Results from Its Rising Multiple Dose Trial with Arimoclomol for ALS
8. Opexa Therapeutics Reports Positive Top-line Data in Phase I/II Extension Trial with Tovaxin for Multiple Sclerosis
9. Velcade (bortezomib) for Injection Survival Data in Front-Line Multiple Myeloma Patients to be Featured at 11th International Myeloma Workshop
10. New Research Demonstrates Broad Efficacy of Azixa (MPC-6827) Against Multiple Tumor Types and in Drug Resistant Cell Lines
11. Orchestra Therapeutics Announces New Phase II Clinical Data on NeuroVax Demonstrating Marked Expansion of Regulatory T Cell Populations in Patients With Multiple Sclerosis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/22/2014)... HAMILTON, N.J. , Oct. 22, 2014 ... CLIA-certified, CAP-accredited laboratory which specializes in high ... that it is now offering new Cystic ... including next- generation DNA sequencing platforms. ... a genetically inherited multisystem disorder that affects ...
(Date:10/22/2014)... , Oct 22, 2014 Antigen Discovery ... Irvine, California , announced the receipt of a ... Innovation Research award (SBIR) from the National Institute of Dental and ... the development of a Pan-HIV Protein Microarray Chip, which ... and HIV-2 subtypes and aid in the development of ...
(Date:10/22/2014)... AVACEN Medical announced today that its AVACEN ... clearance by the U.S. Food and Drug Administration. This ... the Internet for: the temporary relief of joint ... and sprains . Logo - http://photos.prnewswire.com/prnh/20141021/153513 ... is a sophisticated medical device incorporating over 3,000 firmware ...
Breaking Medicine Technology:Medical Diagnostic Laboratories, L.L.C. Institute for Biomarker Research Announces New Prenatal Cystic Fibrosis Tests 2Biomarker Discovery Company, Antigen Discovery Inc., Awarded an NIH Phase I Small Business Innovation Research Grant to Develop a Pan-HIV Protein Microarray Chip 2AVACEN Medical Announces FDA Clearance of First Medical Device with Internal Game Mode 2
... International,Inc. (NYSE: BAX ) announced today that ... IX proteins to treat hemophilia B.,Baxter will develop ... of acute bleeding episodes and a chemically modified, ... of bleeding in,hemophilia B patients. Hemophilia B is ...
... Nanoparticles May Deliver Treatments to Human,Organs -, PHILADELPHIA, ... iron-bearing particles to drive healthy cells to,targeted sites in ... to,a new method of delivering cells and genes to ... http://www.newscom.com/cgi-bin/prnh/20080107/DC10966 ), The study team, led by ...
Cached Medicine Technology:Baxter Announces Recombinant Factor IX Development Program For Hemophilia B 2Baxter Announces Recombinant Factor IX Development Program For Hemophilia B 3Researchers Use Magnetism to Target Cells to Animal Arteries 2Researchers Use Magnetism to Target Cells to Animal Arteries 3Researchers Use Magnetism to Target Cells to Animal Arteries 4
(Date:10/25/2014)... October,s shorter, darker days can trigger a type of ... expert. People affected by seasonal affective disorder, ... and even have trouble getting out of bed. In ... Angelos Halaris, a professor in the department of psychiatry ... of Medicine. "Seasonal affective disorder should not be ...
(Date:10/22/2014)... On October 22, CBS will air ... diseases both fictional and real. The Charles E ... committed to advocacy and philanthropy in the battle against ... opportunity to impart truth and clarity about this misunderstood ... many misconceptions about Morgellons Disease (MD) and ...
(Date:10/22/2014)... 2014 For Dr. Iris Hunter, a job ... an extension of her life’s mission. Her extensive experience in ... owner of FirstLight HomeCare, make it clear that Hunter’s mission ... that my work makes a difference in the lives of ... so after much research, I felt ready to start on ...
(Date:10/22/2014)... Lexington, Kentucky (PRWEB) October 22, 2014 ... an agreement that will change the current location of ... Road to South Limestone across from the University of ... be a state-of-the-art ambulatory care center, owned and operated ... meet the orthopaedic needs of children and their families ...
(Date:10/22/2014)... D.C. (PRWEB) October 22, 2014 With the ... a national survey by the American Institutes for Research (AIR) ... know how to use health insurance, but 42 percent say ... a plan’s details before signing up for coverage. , The ... with only 20 percent able to calculate correctly how much ...
Breaking Medicine News(10 mins):Health News:Dark Days Here for Folks With Seasonal Depression 2Health News:CBS’ Criminal Minds takes aim at skin disease with Morgellons in the Mix 2Health News:CBS’ Criminal Minds takes aim at skin disease with Morgellons in the Mix 3Health News:Dr. Iris Hunter to Host Grand Opening of FirstLight HomeCare Tomorrow 2Health News:Shriners Hospitals for Children - Lexington Announces Plan to Build New $47 Million Facility 2Health News:Shriners Hospitals for Children - Lexington Announces Plan to Build New $47 Million Facility 3Health News:Many Americans Fail to Ask Basic Questions Before Signing Up for Health Insurance, National Survey Finds 2Health News:Many Americans Fail to Ask Basic Questions Before Signing Up for Health Insurance, National Survey Finds 3Health News:Many Americans Fail to Ask Basic Questions Before Signing Up for Health Insurance, National Survey Finds 4
... told yesterday about a surgeon Dr Jerome Blanchard who had ... only a diseased one. , ,The disciplinary hearing ... the wrong kidney from a patient and left her dependent ... medical notes. Dr Jerome Blanchard took out his patient’s transplant ...
... conclusion drawn by the doctors after treating 65 million ... therapy// to bring the blood pressure to normal range ... ,A number of clinical studies since long has shown ... Professor of Medicine; Brigham and Women’s Hospital and Harward ...
... Dutch study contradicts the popular belief that the effect ... impact on the soldier’s partner and children//. It highlights ... any significant way. ,Psychiatrist Arend Veeninga, in ... no scientific basis to the theory that ‘war trauma ...
... has been found to suppress bladder pain associated with ... is a analog of a metabolite of THC, the ... study presented at the annual meeting of the American ... in the treatment of hypersensitive bladder disorders and similar ...
... its presence in the Indian market and gain wider acceptability, ... punch of health// to its India portfolio, possibly by early ... beverage solutions in the non-alcohol segment. This would include not ... Cola India chief Atul Singh told PTI here. ...
... Manchester feel that Statins, A cholesterol-lowering drug should be prescribed ... reduce the heart diseases. ,The researchers looked at ... the mid-1990s, and recorded how many of them had a ... calculate as to how many people would need to have ...
Cached Medicine News:Health News:Consultant Bungles A Kidney Surgery 2Health News:Combination Drug Therapy For Hypertension 2Health News:Bladder Pain Suppressed By Marijuana-Derived Drug 2Health News:A New Study Feels That The UK heart drug Guidelines Not Enough 2
... sunwear, inspired by modern American ... with long lasting wearability. The ... include sophistication, elegance and enduring ... modern shapes, classic styling and ...
... mounting technology has redefined rimless collections forever.,The ... at the end of each frame mounting. ... the bushing that mounts within the lens. ... secure fit is created that far exceeds ...
... collection celebrates the 85th anniversary of the ... feel, the unmistakable icons that made GUCCI ... and sunglass collection, dedicated to a multifaceted ... design that is the hallmark of the ...
... Whisper NG Erbium YAG Extended Ablation laser ... true laser peel with outstanding results and no ... a proprietary fluence level with an extra long ... skin. Peeling is spread over 3-5 days, ...
Medicine Products: